Published in J Immunol on February 01, 1983
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun (1992) 2.66
Antibacterial activity of human natural killer cells. J Exp Med (1989) 1.53
Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin Exp Immunol (1990) 1.51
Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells. Infect Immun (1986) 1.41
Role of natural killer cells in infection with the mouse pneumonitis agent (murine Chlamydia trachomatis). Infect Immun (1987) 1.33
Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Immunol (1985) 1.15
Natural killer cells mediate protection induced by a Salmonella aroA mutant. Infect Immun (1992) 1.15
In vitro effects of natural killer cells against Paracoccidioides brasiliensis yeast phase. Infect Immun (1984) 1.07
Contact of lymphocytes with Helicobacter pylori augments natural killer cell activity and induces production of gamma interferon. Infect Immun (1993) 1.05
Cytotoxicity of human peripheral blood and colostral leukocytes against Shigella species. Infect Immun (1984) 0.98
Natural killer cell activation and interferon production by peripheral blood lymphocytes after exposure to bacteria. Infect Immun (1988) 0.98
Defective NK cell activity following thermal injury. Clin Exp Immunol (1986) 0.96
Bacterial activation of human natural killer cells: role of cell surface lipopolysaccharide. Infect Immun (1988) 0.95
Interferon decreases production of hydrogen peroxide by macrophages: correlation with reduction of suppressive capacity and of anti-microbial activity. Immunology (1983) 0.93
Isolation and functional characterization of chicken intestinal intra-epithelial lymphocytes showing natural killer cell activity against tumour target cells. Immunology (1988) 0.92
Genetic control of in vitro natural cell-mediated activity against Salmonella typhimurium by intestinal and splenic lymphoid cells in mice. Clin Exp Immunol (1984) 0.92
Lymphocyte phenotypes in the intestinal mucosa of sheep infected with Trichostrongylus colubriformis. Clin Exp Immunol (1988) 0.90
Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun (1988) 0.89
Elevated natural killer (NK) cytotoxicity of mononuclear leucocytes from splenectomized patients: increase in Leu-7+ and Leu-11+ leucocytes. Clin Exp Immunol (1986) 0.88
Clearance of Giardia muris infection in mice deficient in natural killer cells. Infect Immun (1986) 0.86
Pretreatment with lipoteichoic acid sensitizes target cells to antibody-dependent cellular cytotoxicity in the presence of anti-lipoteichoic acid antibodies. Infect Immun (1985) 0.84
Potentiation of human natural killer cell cytotoxicity by Salmonella bacteria is an interferon- and interleukin-2-independent process that utilizes CD2 and CD18 structures in the effector phase. Infect Immun (1991) 0.82
Mucosal lymphocytes in the rat small intestine: phenotypical characterization in situ. Immunology (1986) 0.80
Requirement and redundancy of the Src family kinases Fyn and Lyn in perforin-dependent killing of Cryptococcus neoformans by NK cells. Infect Immun (2013) 0.79
Modulation of in vitro natural cell-mediated activity against enteropathogenic bacteria by simple sugars. Infect Immun (1985) 0.78
Cytotoxicity of leukocytes from normal and Shigella-susceptible (opium-treated) guinea pigs against virulent Shigella sonnei. Infect Immun (1984) 0.75
Mutants of pertussis toxin suitable for vaccine development. Science (1989) 2.89
Characteristics of natural killer cells in the murine intestinal epithelium and lamina propria. J Exp Med (1982) 2.12
Dissecting human T cell responses against Bordetella species. J Exp Med (1988) 2.07
Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem (1997) 1.97
Is videopupillography useful in the diagnosis of Alzheimer's disease? Neurology (1998) 1.87
Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83
Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J Virol (1992) 1.80
Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine (1992) 1.78
Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res (1990) 1.77
Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol (1984) 1.75
Morphological characterization of a cell population responsible for natural killer activity. Immunology (1981) 1.73
Natural killer activity of gut mucosal lymphoid cells in mice. Eur J Immunol (1981) 1.73
Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA. Nature (1984) 1.71
Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell (1996) 1.57
Multi-frequency impedance for the prediction of extracellular water and total body water. Br J Nutr (1995) 1.57
Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med (1989) 1.49
Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice. J Immunol (1979) 1.48
Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. Leuk Res (1997) 1.48
Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica (1999) 1.46
Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Exp Cell Res (1996) 1.45
Natural cytotoxicity of mouse monocytes and macrophages. J Immunol (1979) 1.43
Non-cemented total hip replacement for metastatic disease. Orthopedics (1993) 1.39
Absence of protective immunity against diphtheria in a large proportion of young adults. Vaccine (1993) 1.35
Macrophage activation for tumor cytotoxicity: analysis of intermediary reactions. J Reticuloendothel Soc (1979) 1.31
Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect Immun (1991) 1.31
A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J Immunol (1986) 1.30
IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol (1986) 1.30
Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med (1990) 1.30
CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid. Antimicrob Agents Chemother (2004) 1.26
Discriminative and predictive power of an informant report in mild cognitive impairment. J Neurol Neurosurg Psychiatry (2006) 1.25
IgA-dependent cell-mediated activity against enteropathogenic bacteria: distribution, specificity, and characterization of the effector cells. J Immunol (1984) 1.24
Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid. J Infect Dis (1980) 1.24
The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol (1998) 1.24
Expanding drug resistance through integron acquisition by IncFI plasmids of Salmonella enterica Typhimurium. Emerg Infect Dis (2001) 1.22
Regulation of arachidonic acid metabolism in macrophages by immune and nonimmune interferons. J Immunol (1985) 1.17
The reproducibility of subjective appetite scores. Br J Nutr (1995) 1.17
In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta. J Immunol (1987) 1.16
Natural anti-bacterial activity against Salmonella typhi by human T4+ lymphocytes armed with IgA antibodies. J Immunol (1985) 1.16
Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest (1996) 1.15
Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Immunol (1985) 1.15
Two-dimensional electrophoretic patterns of acute-phase human serum proteins in the course of bacterial and viral diseases. Electrophoresis (1996) 1.14
Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones. Proc Natl Acad Sci U S A (1992) 1.12
Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obes Rev (2011) 1.12
Macrophage activation for tumor cytotoxicity: genetic variation in macrophage tumoricidal capacity among mouse strains. Cell Immunol (1979) 1.11
Resistant starch: the effect on postprandial glycemia, hormonal response, and satiety. Am J Clin Nutr (1994) 1.10
Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem (2001) 1.10
Priming to heat shock proteins in infants vaccinated against pertussis. J Immunol (1993) 1.09
PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it. Ann Rheum Dis (2005) 1.09
Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses. Int J Immunopharmacol (1981) 1.08
New hemolytic method for determination of antistreptolysin O in whole blood. J Clin Microbiol (1978) 1.08
Comparison of multidrug resistance gene regions between two geographically unrelated Salmonella serotypes. J Antimicrob Chemother (2005) 1.08
Defective tumoricidal capacity of macrophages from A/J mice. I. Characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli. J Immunol (1979) 1.07
Differential binding of IL-1 alpha and IL-1 beta to receptors on B and T cells. FEBS Lett (1989) 1.05
Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett (2001) 1.05
In vitro generated mast cells express natural cytotoxicity against tumour cells. Immunology (1985) 1.05
IFN-beta-induced reduction of superoxide anion generation by macrophages. Immunology (1982) 1.04
Interferon-induced enhancement of macrophage-mediated tumor cytolysis and its difference from activation by lymphokines. Eur J Immunol (1981) 1.04
Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem (1997) 1.02
Evaluation of nutritional status in children with refractory epilepsy. Nutr J (2006) 1.02
Progress towards the development of new vaccines against whooping cough. Vaccine (1992) 1.02
A monoclonal antibody to the IL-1 beta peptide 163-171 blocks adjuvanticity but not pyrogenicity of IL-1 beta in vivo. J Immunol (1989) 1.02
Defective tumoricidal capacity of macrophages from A/J mice. III. Genetic analysis of the macrophage defect. J Immunol (1980) 1.02
Interferon inhibits prostaglandin biosynthesis in macrophages: effects on arachidonic acid metabolism. J Immunol (1984) 1.02
Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule. Infect Immun (1992) 1.02